For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5B, representing growth of 45% compared to Q4 2023. This includes approximately $3.5B for Mounjaro and $1.9B for Zepbound. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and neuroscience medicines in Q4 of 2024. In total, non-incretin revenue grew by 20% compared to Q4 2023. However, the company’s expected 2024 revenue is $400M, or about 3%, below the guidance range issued on October 30, 2024, as part of the Q3 2024 earnings call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) Expects Weight-Loss Pill Approval in 2026
- Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
- Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
- Verve Therapeutics announces anticipated 2025 milestones
- Potential acquisition of Scorpion positive for Relay, says Barclays